J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Tables
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bloomfield, D. M.
Right arrow Articles by Wagner, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bloomfield, D. M.
Right arrow Articles by Wagner, J. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PHARMACODYNAMICS

A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects

Daniel M. Bloomfield, MD, Rajesh Krishna, PhD, FCP, David Hreniuk, BS, Lisa Hickey, PhD, Kalyan Ghosh, PhD, Arthur J. Bergman, PhD, Jutta Miller, BS, Maria J. Gutierrez, MD, Randall Stoltz, MD, Keith M. Gottesdiener, MD, Gary A. Herman, MD and John A. Wagner, MD, PhD

From Merck & Company Inc, Whitehouse Station, New Jersey (Dr Bloomfield, Dr Krishna, Hreniuk, Hickey, Ghosh, Bergman, Miller, Gottesdiener, Herman, Wagner); Comprehensive Phase One, Miramar, Florida (Gutierrez); and Covance-GFI, Evansville, Indiana (Stoltz).

A randomized, double-blind, placebo-controlled, 4-period crossover study was performed with a single oral dose of sitagliptin (100 mg, 800 mg), moxifloxacin (400 mg), and placebo in order to provide a rigorous assessment of the effect of sitagliptin on ventricular repolarization based on the ICH E14 guidance. The clinical dose of sitagliptin 100 mg was not associated with an increase in QTc interval, corrected using the Fridericia correction (QTcf), at any time point. The supratherapeutic 800-mg dose of sitagliptin was generally well tolerated and was associated with minimal, clinically insignificant prolongation of the QTcf interval at concentrations approximately 11-fold higher than maximal concentrations following the 100-mg clinical dose. The PK/QTc model demonstrated a shallow relationship between the plasma concentration of sitagliptin and the placebo-subtracted QTcf change from baseline, with a 0.59-millisecond increase in QTc for every 1000-nM increment in sitagliptin plasma concentration. The sensitivity of the assay to detect modest increases in QTc interval was established with the active control moxifloxacin. In conclusion, at clinically relevant concentrations, sitagliptin is not associated with clinically meaningful QTcf prolongation.

Key Words: QTc interval • sitagliptin • moxifloxacin

Address for reprints: Daniel M. Bloomfield, MD; e-mail: daniel_bloomfield{at}merck.com; and Rajesh Krishna, PhD, FCP, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, NJ 07065; e-mail: rajesh_krishna{at}merck.com.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American College of Clinical Pharmacology